Literature DB >> 26898755

Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.

A Kumar1, M Singhal1, C Chopra1, S Srinivasan1, R P Surabhi1, R Kanumuri1, S Tentu1, S Jagadeeshan1, S Sundaram2, K Ramanathan2, R Shankar Pitani3, B Muthuswamy4, S Abhijit4, A S Nair5, G Venkatraman6, S K Rayala1.   

Abstract

P21 Activated Kinase 1 (Pak1), an oncogenic serine/threonine kinase, is known to have a significant role in the regulation of cytoskeleton and cellular morphology. Runx3 was initially known for its role in tumor suppressor function, but recent studies have reported the oncogenic role of Runx3 in various cancers. However, the mechanism that controls the paradoxical functions of Runx3 still remains unclear. In this study, we show that Runx3 is a physiologically interacting substrate of Pak1. We identified the site of phosphorylation in Runx3 as Threonine 209 by mass spectrometry analysis and site-directed mutagenesis, and further confirmed the same with a site-specific antibody. Results from our functional studies showed that Threonine 209 phosphorylation in Runx3 alters its subcellular localization by protein mislocalization from the nucleus to the cytoplasm and subsequently converses its biological functions. This was further supported by in vivo tumor xenograft studies in nude mouse models which clearly demonstrated that PANC-28 cells transfected with the Runx3-T209E clone showed high tumorigenic potential as compared with other clones. Our results from clinical samples also suggest that Threonine 209 phosphorylation by Pak1 could be a potential therapeutic target and of great clinical relevance with implications for Runx3 inactivation in cancer cells where Runx3 is known to be oncogenic. The findings presented in this study provide evidence of Runx3-Threonine 209 phosphorylation as a molecular switch in dictating the tissue-specific dualistic functions of Runx3 for the first time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26898755     DOI: 10.1038/onc.2016.18

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Oncogenic potential of the RUNX gene family: 'overview'.

Authors:  Yoshiaki Ito
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 2.  p21-activated kinases in cancer.

Authors:  Rakesh Kumar; Anupama E Gururaj; Christopher J Barnes
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

3.  RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.

Authors:  Xin-Zi Chi; Jeung-Ook Yang; Kwang-Youl Lee; Kosei Ito; Chohei Sakakura; Qing-Lin Li; Hye-Ryun Kim; Eun-Jeung Cha; Yong-Hee Lee; Atsushi Kaneda; Toshikazu Ushijima; Wun-Jae Kim; Yoshiaki Ito; Suk-Chul Bae
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

Authors:  Wun-Jae Kim; Eun-Jung Kim; Pildu Jeong; Changyi Quan; Jiyeon Kim; Qing-Lin Li; Jeong-Ook Yang; Yoshiaki Ito; Suk-Chul Bae
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

5.  Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.

Authors:  Naoki Yanagawa; Gen Tamura; Hiroyuki Oizumi; Nobumasa Takahashi; Yasuhisa Shimazaki; Teiichi Motoyama
Journal:  Cancer Sci       Date:  2003-07       Impact factor: 6.716

Review 6.  Tumor suppressor activity of RUNX3.

Authors:  Suk-Chul Bae; Joong-Kook Choi
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 7.  RUNX family: Regulation and diversification of roles through interacting proteins.

Authors:  Linda Shyue Huey Chuang; Kosei Ito; Yoshiaki Ito
Journal:  Int J Cancer       Date:  2012-12-19       Impact factor: 7.396

8.  Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm.

Authors:  Yun-Mi Goh; Senthilkumar Cinghu; Eileen Tan Hwee Hong; You-Soub Lee; Jang-Hyun Kim; Ju-Won Jang; Ying-Hui Li; Xin-Zi Chi; Kyeong-Sook Lee; Heejun Wee; Yoshiaki Ito; Byung-Chul Oh; Suk-Chul Bae
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

9.  Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer.

Authors:  Y-H Nicole Tsang; X-W Wu; J-S Lim; C Wee Ong; M Salto-Tellez; K Ito; Y Ito; L-F Chen
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

10.  RUNX3 has an oncogenic role in head and neck cancer.

Authors:  Takaaki Tsunematsu; Yasusei Kudo; Shinji Iizuka; Ikuko Ogawa; Tsuyoshi Fujita; Hidemi Kurihara; Yoshimitsu Abiko; Takashi Takata
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

View more
  5 in total

1.  EZH2 regulates a SETDB1/ΔNp63α axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma.

Authors:  Seamus Balinth; Matthew L Fisher; Yon Hwangbo; Caizhi Wu; Carlos Ballon; Xueqin Sun; Alea A Mills
Journal:  Oncogene       Date:  2022-07-21       Impact factor: 8.756

Review 2.  Emerging role of RUNX3 in the regulation of tumor microenvironment.

Authors:  Sarala Manandhar; You Mie Lee
Journal:  BMB Rep       Date:  2018-04       Impact factor: 4.778

3.  Inhibition of PIM1 attenuates the stem cell-like traits of breast cancer cells by promoting RUNX3 nuclear retention.

Authors:  Hui Liu; Cheng Chen; Dongshen Ma; Yubing Li; Qianqian Yin; Qing Li; Chenxi Xiang
Journal:  J Cell Mol Med       Date:  2020-04-19       Impact factor: 5.310

4.  Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India.

Authors:  Asad Ur Rehman; Mohammad Askandar Iqbal; Real Sumayya Abdul Sattar; Snigdha Saikia; Mohammad Kashif; Wasif Mohammad Ali; Subhash Medhi; Sundeep Singh Saluja; Syed Akhtar Husain
Journal:  Cancer Cell Int       Date:  2020-09-10       Impact factor: 5.722

Review 5.  p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond.

Authors:  Xiaodong Li; Feng Li
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.